Oxford Biobank Scientific Coordinator
I am the Oxford Biobank and Bioresource Scientific Coordinator, primarily responsible for curation of the Oxford Biobank (OBB) genetic resource and facilitator of Bioresource recruit-by-genotype and recruit-by-phenotype translational research studies available to the Metabolic Research Group (MRG), the larger research community and Industry. My primary research interests focus on understanding the genetic determinants of body fat function and distribution and how this may impact, and be utilised to improve, the health consequences of obesity. Other duties include primary genetic data interrogator and analyst for the MRG, DPhil student supervisor, Lecturer and dissertation supervisor on the Experimental and Translational Therapeutics MSc program and Chair of the senior academic faculty for the OCDEM building.
I completed my DPhil in 2000 in human molecular genetics (Ox) followed by 2 years of R&D in industry (TWT, Madison, Wisconsin, US) working on marketable novel genetic assay systems. Previous research has included the contribution of genetics to smoking addiction and cessation within the General Practice Research group (Ox) and collaborations within the Department of Gastroenterology (Ox), imputing extended HLA haplotypes for association studies with autoimmune diseases such as Irritable Bowel Disease and Behçet's disease. In 2003 I took on a Postdoctoral Researcher position with Prof Fredrik Karpe investigating the genetics of Adipose tissue function and the adverse consequences of Obesity and Type II Diabetes. As a progression from his previous roles within the MRG and the Oxford Biobank I then took on the BRC funded position of Oxford Biobank and Bioresource Scientific Coordinator in 2012.
MLX plays a key role in lipid and glucose metabolism in humans: evidence from in vitro and in vivo studies
NAGARAJAN S. et al, (2023), Metabolism: clinical and experimental
Type 2 Diabetes risk alleles in Peptidyl-glycine Alpha-amidating Monooxygenase influence GLP-1 levels and response to GLP-1 Receptor Agonists.
Umapathysivam MM. et al, (2023), medRxiv
Polygenic risk in Type III hyperlipidaemia and risk of cardiovascular disease: An epidemiological study in UK Biobank and Oxford Biobank.
Pieri K. et al, (2022), Int J Cardiol
A saturated map of common genetic variants associated with human height.
Yengo L. et al, (2022), Nature, 610, 704 - 712
High-throughput mass spectrometry maps the sepsis plasma proteome and differences in response
Mi Y. et al, (2022)